Who we are
Our team shares a common goal of giving patients a better, longer life. We use the best science to improve the health and quality of life of patients and their carers
Supported by our parent company, Affitech Research AS, we are building a pipeline around the delivery of carefully planned and delivered clinical trials in the UK, Europe, US, and other major markets for biologicals targeting unmet medical needs.
Find out more about the Team-
Collaborative
Through collaboration with our trusted, well established pharmaceutical partners, we’re committed to offering solutions to patients.
-
Experts
As specialists in inventive trial designs, we know the importance of tailoring those designs to the needs of the individual, and we work to improve the lives of patients who need our help most.
-
Patient-focused
Our industry leading team is in pursuit of a future that improves the lives of those who need our help the most, consistently driving and pushing progress toward improving the real-life impact of rare diseases.
Trialing Innovative Therapies
We are experienced in the identification and early development of biological medicines for human diseases with unmet medical needs. The team previously worked on the development of therapeutic agents with Roche and Generium.
We have a long-standing partnership with Generium and a collaboration with them to develop GNR-055, a recombinant fusion protein for mucopolysaccharidosis II (MPS II, Hunter syndrome).
Find out more about our MPS II clinical trial